HK1096406B - Novel method for the synthesis of perindopril and the pharmaceutiucally acceptable salts thereof - Google Patents

Description

Novel method for the synthesis of perindopril and its pharmaceutically acceptable salts

The present invention relates to a process for the synthesis of perindopril of formula (I) and the pharmaceutically acceptable salts thereof.

Perindopril and its pharmaceutically acceptable salts, more particularly its tert-butylamine salt, have valuable pharmacological properties.

Their main properties are the inhibition of angiotensin I converting enzyme (or kininase II), which on the one hand prevents the conversion of the decapeptide angiotensin I to the octapeptide angiotensin II (vasoconstrictor) and on the other hand prevents the degradation of bradykinin (vasodilator) to an inactive peptide.

These two effects contribute to the beneficial effects of perindopril in cardiovascular diseases, more particularly in arterial hypertension and heart failure.

Perindopril, its preparation and its use in therapeutics are described in european patent specification EP 0049658.

In view of the pharmaceutical value of this compound, it is important to be able to obtain it by an efficient synthetic process which can be easily converted to industrial scale, which process makes it possible to produce perindopril in high yield and excellent purity starting from a reasonably priced starting material.

Patent application EP 0308341 describes the synthesis of perindopril by coupling (2S, 3aS, 7aS) -benzyl octahydroindole-2-carboxylate and ethyl N- [ (S) -1-carboxybutyl ] - (S) -alanine, followed by deprotection of the carboxylic acid group of the heterocycle by catalytic hydrogenation.

The applicant has now developed a new process for the synthesis of perindopril using readily available starting materials.

More specifically, the present invention relates to a process for the synthesis of perindopril and the pharmaceutically acceptable salts thereof, characterized in that: reacting a compound of formula (II) in the presence of a base

Wherein R represents a hydrogen atom or a benzyl group or a linear or branched (C)₁-C₆) An alkyl group, a carboxyl group,

with a compound of formula (III) having the (R) configuration,

wherein G represents a chlorine, bromine or iodine atom, or a hydroxyl, p-toluenesulfonyloxy, methanesulfonyloxy or trifluoromethanesulfonyloxy group,

to generate the compound shown in the formula (IV),

wherein R and G are as previously defined,

reacting a compound of formula (IV) with a compound of formula (V) having the (S) configuration,

if desired after deprotection to give the compounds of formula (I).

Among the bases which can be used for the reaction between the compounds of formulae (II) and (III), mention may be made, without implying any limitation, of organic amines, such as triethylamine, pyridine and diisopropylethylamine, and inorganic bases, such as NaOH, KOH, Na₂CO₃、K₂CO₃、NaHCO₃And KHCO₃。

When G represents a chlorine, bromine or iodine atom, or a p-toluenesulfonyloxy, methanesulfonyloxy or trifluoromethanesulfonyloxy group, the reaction between the compounds of formulae (IV) and (V) is preferably carried out in the presence of a base, preferably an organic amine such as triethylamine, pyridine and diisopropylethylamine, or an inorganic base such as Na₂CO₃、K₂CO₃、NaHCO₃Or KHCO₃。

When G represents a hydroxyl group, the reaction between the compounds of formulae (IV) and (V) is preferably carried out in the presence of activating reagents such as N-methyl-N-phenyl-aminotriphenylphosphonium iodide or hexamethylphosphoric triamide and ammonium perchlorate, or by a Mitsunobu reaction when R is not a hydrogen atom.

The compounds of formula (IV) wherein G represents a chlorine atom or a p-toluenesulfonyloxy or methanesulfonyloxy group are novel products useful as synthesis intermediates in the chemical or pharmaceutical industry, especially in the synthesis of perindopril and as such form part of the building blocks of the present invention.

Example 1: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) butylamino]-propionyl } octahydro-1H-indole-2-carboxylic acid tert-butylamine salt

Step A: (2S, 3aS, 7aS) -1- [ (2R) -2-Bromopropionyl group]octahydro-1H-indole-2-carboxylic acid benzyl ester

200g of benzyl (2S, 3aS, 7aS) -octahydro-1H-indole-2-carboxylate and 1.5L of dichloromethane are placed in a reactor, the temperature of the reaction mixture is then brought to 0 ℃ and 201ml of diisopropylethylamine and then 132g of (2R) -2-bromopropionyl chloride are added. Subsequently, the temperature of the mixture was brought to ambient temperature. After stirring at this temperature for 1 hour, the mixture was washed with water and then with a dilute acetic acid solution. The benzyl (2S, 3aS, 7aS) -1- [ (2R) -2-bromopropionyl ] octahydro-1H-indole-2-carboxylate solution thus obtained was used aS such in the next step.

Step B: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) butylamino]-CAcyl } octahydro-1H-indole-2-carboxylic acid benzyl ester

123g of ethyl (2S) -2-aminopentanoate, 160ml of triethylamine and 160ml of acetonitrile were placed in a reactor, and then the temperature of the mixture was brought to 60 ℃ and the solution obtained in step A was slowly added and refluxed for 4 hours. After returning to ambient temperature, the mixture was washed with water and dilute acetic acid solution and the solvent was evaporated off to give benzyl (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) butylamino ] -propionyl } octahydro-1H-indole-2-carboxylate.

Step C: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) butylamino]-propionyl } octahydro-1H-indole-2-carboxylic acid

200g of the compound obtained in the above step in acetic acid solution and then 5g of 10% Pd/C were placed in a hydrogenation vessel. Hydrogenation at 15 to 30 ℃ under a pressure of 0.5 bar until the theoretical amount of hydrogen has been absorbed. The catalyst was removed by filtration, then cooled to 0 to 5 ℃ and the resulting solid recovered by filtration. The filter cake was washed and dried to constant weight. Thus, (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) butylamino ] -propionyl } octahydro-1H-indole-2-carboxylic acid was obtained in 85% yield and 99% enantiomeric purity.

Step D: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) butylamino]-propionyl } octahydro-1H-indole-2-carboxylic acid tert-butylamine salt

The precipitate (200g) obtained in the above step was dissolved in 2.8L of ethyl acetate, followed by addition of 40g of tert-butylamine and 0.4L of ethyl acetate.

The resulting suspension is then refluxed until complete dissolution, and the resulting solution is then filtered under heating and cooled to a temperature of 15 to 20 ℃ while stirring.

The resulting precipitate was then filtered off, made into a paste with ethyl acetate, dried and then crushed to give the desired product in 95% yield.

Example 2: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxy)Carbonyl) butylamino]-propionyl } octahydro-1H-indole-2-carboxylic acid tert-butylamine salt

Step A: (2S, 3aS, 7aS) -1- [ (2R) -2-Bromopropionyl group]octahydro-1H-indole-2-carboxylic acid

200g of (2S, 3aS, 7aS) -octahydro-1H-indole-2-carboxylic acid, 75ml of water and 150ml of toluene were placed in a reactor, and then the temperature of the mixture was made 0-5 ℃ and 250ml of 5M sodium hydroxide solution was added, followed by addition of 202g of a toluene solution of (2R) -2-bromopropionyl chloride while keeping the temperature below 10 ℃ and addition of 5M sodium hydroxide solution to keep the pH of the mixture at 10. After stirring at 10 ℃ for a further 1h, concentrated hydrochloric acid was added and the pH of the mixture was adjusted to 6.

The toluene phase was separated and concentrated hydrochloric acid was then added to the aqueous phase to adjust the pH to 2.

The precipitate formed is then filtered off and dried to give (2S, 3aS, 7aS) -1- [ (2R) -2-bromopropionyl ] octahydro-1H-indole-2-carboxylic acid.

Step B: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) butylamino]-propionyl } octahydro-1H-indole-2-carboxylic acid

105g of ethyl (2S) -2-aminopentanoate, 135ml of triethylamine and 135ml of acetonitrile were put into a reactor, and then a solution of 200g of the compound obtained in step A in 1.3L of dichloromethane was slowly added thereto while the temperature of the mixture was made 60 ℃, followed by refluxing for 4 hours. After returning to ambient temperature, the mixture was washed with water and dilute acetic acid solution, and then the solvent was distilled off to give (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) butylamino ] -propionyl } octahydro-1H-indole-2-carboxylic acid.

Step C: same as step D of example 1.

Example 3: (2S, 3aS, 7aS) -1- { (2S) -2- [ (1S) -1- (ethoxycarbonyl) butylamino]-propionyl } octahydro-1H-indole-2-carboxylic acid tert-butylamine salt

Step A：(2S，3aS，7aS)-1-[(2R)-2-{P-toluenesulfonyloxy } propanoyl group]Benzyl (octahydro-1H-indole-2-carboxylate)

200g of (2S, 3aS, 7aS) -octahydro-1H-indole-2-carboxylic acid benzyl ester and 1.5L of dichloromethane are placed in a reactor, the temperature of the reaction mixture is then brought to 0 ℃ and 201ml of diisopropylethylamine and 202g of (1R) -2-chloro-1-methyl-2-oxoethyl p-toluenesulfonate are added. Subsequently, the temperature of the mixture was brought to ambient temperature. After stirring at this temperature for 1 hour, the mixture was washed with water. The benzyl (2S, 3aS, 7aS) -1- [ (2R) -2- { p-toluenesulfonyloxy } propanoyl ] -octahydro-1H-indole-2-carboxylate solution thus obtained was used aS such in the next step.

Steps B to D: the same procedure as in steps B to D of example 1 was repeated.

Claims (8)

1. A process for the synthesis of compounds of formula (I) and pharmaceutically acceptable salts thereof,

the method is characterized in that: reacting a compound of formula (II) in the presence of a base

Wherein R represents a hydrogen atom or a benzyl group or a linear or branched C₁-C₆An alkyl group, a carboxyl group,

with a compound of formula (III) having the (R) configuration,

wherein G represents a chlorine, bromine or iodine atom, or a hydroxyl, p-toluenesulfonyloxy, methanesulfonyloxy or trifluoromethanesulfonyloxy group,

to generate the compound shown in the formula (IV),

wherein R and G are as previously defined,

reacting a compound of formula (IV) with a compound of formula (V) having the (S) configuration,

if desired after deprotection to give the compounds of formula (I).

2. Synthesis process according to claim 1, characterized in that the base used for the reaction between the compounds of formulae (H) and (III) is an organic amine selected from triethylamine, pyridine and diisopropylethylamine or is selected from NaOH, KOH, Na₂CO₃、K₂CO₃、NaHCO₃And KHCO₃The inorganic base of (1).

3. A synthesis process according to claim 1, characterized in that G represents a chlorine or bromine atom, or a p-toluenesulfonyloxy, methanesulfonyloxy or trifluoromethanesulfonyloxy group.

4. According to the claimsThe synthesis process according to claim 3, characterized in that the reaction between the compounds of formulae (IV) and (V) is carried out in the presence of an organic amine selected from triethylamine, pyridine and diisopropylethylamine or in the presence of Na₂CO₃、K₂CO₃、NaHCO₃And KHCO₃In the presence of an inorganic base.

5. A synthesis process according to claim 1, characterized in that G represents a hydroxyl group.

6. The synthesis according to claim 5, characterized in that the reaction between the compounds of formulae (IV) and (V) is carried out in the presence of an activating reagent selected from N-methyl-N-phenyl-aminotriphenylphosphonium iodide and hexamethylphosphoric triamide and ammonium perchlorate, or by a Mitsunobu reaction when R is not a hydrogen atom.

7. A compound of the formula (IV),

wherein R represents a hydrogen atom or a benzyl group or a linear or branched C₁-C₆Alkyl, G represents a chlorine atom or a p-toluenesulfonyloxy or methanesulfonyloxy group.

8. A process according to any one of claims 1 to 6, for the synthesis of perindopril in the form of a tert-butylamine salt.